Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient’s demographic and clinical history. Despite the numerous studies conducted on platelet function and on the role of plasma factors, an accurate and reliable method to dynamically quantify the hypercoagulability states of these conditions is not yet part of clinical practice. Starting from our experience, and after having sifted through the literature, we propose an in-depth narrative report on the contribution of the clonal platelets of MPNs—rich in tissue factor (TF)—in promoting a perpetual procoagulant mechanism. The whole process results in an unbalanced generation of thrombin and is self-maintained by Protease Activated Receptors (...
Thromboembolic complications are the most common causes of morbidity and mortality in patients with ...
Abstract Background Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythem...
In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombo...
Classical myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders that manifest wi...
Introduction: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN), pol...
The platelet contribution to the thrombophilic state of patients with myeloproliferative neoplasms (...
In spite of their recognized risk of thrombosis, patients with myeloproliferative neoplasms (MPN) sh...
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR...
Background: Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera ...
Platelets are conventionally defined as playing a vital role in homeostasis and thrombosis. This rol...
Philadelphia-negative myeloproliferative neoplasms are considered to be acquired thrombophilic state...
Thrombosis is a leading cause of morbidity and mortality in patients with Philadelphia chromosome–ne...
In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombo...
Life expectancy of patients with myeloproliferative neoplasms (MPNs) and particularly that of subjec...
Polycythemia vera (PV) and essential thrombocythemia (ET) are two Philadelphia-negative myeloprolife...
Thromboembolic complications are the most common causes of morbidity and mortality in patients with ...
Abstract Background Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythem...
In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombo...
Classical myeloproliferative neoplasms (MPNs) are hematopoietic stem cell disorders that manifest wi...
Introduction: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN), pol...
The platelet contribution to the thrombophilic state of patients with myeloproliferative neoplasms (...
In spite of their recognized risk of thrombosis, patients with myeloproliferative neoplasms (MPN) sh...
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR...
Background: Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera ...
Platelets are conventionally defined as playing a vital role in homeostasis and thrombosis. This rol...
Philadelphia-negative myeloproliferative neoplasms are considered to be acquired thrombophilic state...
Thrombosis is a leading cause of morbidity and mortality in patients with Philadelphia chromosome–ne...
In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombo...
Life expectancy of patients with myeloproliferative neoplasms (MPNs) and particularly that of subjec...
Polycythemia vera (PV) and essential thrombocythemia (ET) are two Philadelphia-negative myeloprolife...
Thromboembolic complications are the most common causes of morbidity and mortality in patients with ...
Abstract Background Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythem...
In patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs), the anti-thrombo...